The End of Trial and Error.
End-to-end simulation from molecule to market. Discover candidates, de-risk trials, pick the right cohort, validate the path.
Every prediction traceable to its source. No black boxes.
Over 90% of drugs entering clinical trials fail to reach approval. Most late-stage failures are traceable to problems that were present before the trial began: the wrong dose, the wrong patient population, the wrong endpoint. None of them required a failed trial to discover. They required a better model.
Where are you in your program?
OVIVO connects the full biological chain — from a patient's genetics through drug absorption, metabolism, receptor engagement, pathway modulation, and disease progression — and translates it into the clinical endpoints that trials actually measure. Every prediction carries an honest uncertainty bound. Find your situation below.
Discovering a new drug
Start with what the disease needs. Identify targets from biological gaps, generate candidates, validate them through the full simulation chain.
Explore discovery →
A program is stuck
Wrong dose? Failed endpoint? Repurpose or kill? Simulate the next move across the full chain before you commit the spend.
Explore simulations →
Choosing the right cohort
Predict trial outcomes by patient population. Find the cohort where your drug actually works — before any patient enrolls.
Explore trials →
Treating a complex case
Rare, treatment-resistant, or off-protocol. Run the full platform at the level of one patient — their genetics, their disease, their current treatment.
Explore precision medicine →Validated. Independently verifiable. And growing.
A prediction that cannot be traced back to its inputs is not a prediction. It is an opinion. Every number OVIVO produces has a chain of custody — the data source, the confidence level, the calculation method. Mechanistic. Traceable. Honest.
For Pharma, Biotech and CROs
Co-development partnerships for trial design, pipeline de-risking, competitive analysis, drug repurposing, and combination strategy. We're actively looking for partners.
develop@ovivolabs.comFor Investors
A demonstrable, independently verifiable prediction record across drug development's most expensive failure points. Growing validation library. Clear trajectory.
invest@ovivolabs.comFor Patients and Clinical Teams
For complex, rare, or treatment-resistant cases where the standard pathway offers limited answers. This is research data, not clinical advice. Clinical decisions belong with your team.
info@ovivolabs.com